News

Recreating the respiratory tract in a dish: Modeling viral infections and testing treatments
A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...
Timing of RSV immunization matters for infant protection
The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...
Pulmonology Advisor1d
Infant RSV Prevention: Efforts Needed to Improve Uptake of Vaccines, Treatments
Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.
Vietnam Investment Review10d
The Lancet Publishes Ziresovir Phase III RSV Trial in Infants Under 6 Months
Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's ...
Pharmaceutical Technology on MSN8d
ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59
The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.
The Manila Times10d
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the ...
Managed Healthcare Executive3d
A Win for Adult RSV Vaccination Amid Vaccine Uncertainty, Hesitancy
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Medscape1d
2025 Begins With 112 Drugs Waiting for Approval in Europe
Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...
Experts make new recommendations on RSV and meningitis vaccines, but it’s unclear what happens next
ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...
PharmExec9d
ArkBio’s Ziresovir Demonstrates Clinical Efficacy in Hospitalized Infants with Respiratory Syncytial Virus
Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...
Yahoo Finance10d
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
With millions of cases annually worldwide, especially among infants under six months, RSV imposes a significant burden on families and healthcare systems. Current treatments are limited to ...